Follistatin-344 for Muscle Preservation

Candidate profile

Adults at risk of significant muscle wasting — from sarcopenia, prolonged immobilization, aggressive caloric restriction, or catabolic conditions where lean mass preservation is a priority.

Follistatin-344 is firmly investigational. Evidence derives from preclinical models and gene therapy studies, not completed RCTs of injectable peptide. This is a research-stage intervention for informed individuals.

Approach

Subcutaneous follistatin-344 administration to inhibit myostatin (GDF-8) and activin A — two TGF-beta family members that serve as the body's primary brakes on muscle growth. By neutralizing these ligands, follistatin shifts the balance toward muscle protein synthesis and satellite cell activation. The mechanism is not anabolic in the way testosterone or GH are — follistatin removes an inhibitory signal rather than providing a stimulatory one.

Protocol design

Primary peptide: Follistatin-344, approximately 100 mcg daily

Route: Subcutaneous injection

Timing: Morning (timing relative to meals is not well characterized)

Cycle length: 10–30 days, followed by extended off periods — limited long-term safety data and potential for immune-mediated clearance mandate short cycles

Frequency: Daily during the active cycle

Dosing context: The 100 mcg figure derives from practitioner protocols, not clinical dose-ranging studies. Direct translation from preclinical gene-therapy models is uncertain.

Optional supportive stack:

• IGF-1 LR3, 20–50 mcg daily — provides growth factor signaling that complements myostatin inhibition
• MGF (Mechano Growth Factor), 100–200 mcg post-training — local satellite cell activation in exercised muscle groups

Timeline & milestones

Days 1–7: No measurable changes expected. Follistatin's mechanism operates through gene expression modulation, which requires days to weeks for functional protein-level changes.

Days 7–14: Early signals in some users: improved training recovery, reduced DOMS, and a subjective sense of muscle fullness. These are consistent with reduced catabolic signaling but difficult to distinguish from placebo.

Days 14–30: The window where measurable lean mass preservation is most plausible. During caloric restriction, the expected lean mass loss may be attenuated. During maintenance or surplus, modest accrual beyond training alone is the reported outcome — though controlled data is absent.

Post-cycle: Effects may persist for 2–4 weeks after cessation as myostatin-inhibited signaling returns to baseline.

Monitoring

• Lean body mass: DEXA scan at baseline and end of cycle — the only objective outcome that matters
• Strength testing: Track compound lifts weekly. Strength maintenance during a deficit is a positive signal
• Complete blood count: Activin signaling affects erythropoiesis — monitor for hematological changes
• Liver and kidney panels: Baseline and post-cycle to screen for organ stress
• Anti-follistatin antibodies: If repeating cycles, test for neutralizing antibodies

When to adjust

• No measurable lean mass preservation by end of cycle: Reassess rather than escalate — increasing beyond 100 mcg has no supporting data.
• Injection site reactions: May indicate immune response. Discontinue and allow resolution before re-challenge.
• Systemic symptoms (fatigue, malaise): Follistatin interacts with TGF-beta ligands beyond myostatin. Unexpected effects warrant immediate discontinuation.
• Reproductive concerns: Activin A regulates FSH. Individuals planning conception should avoid follistatin-344.

Evidence reality check

Myostatin inhibition is a validated target — knockout animals show dramatic hypertrophy across species, and the Mendell et al. gene therapy trial in Becker muscular dystrophy confirmed functional improvements. But injectable follistatin-344 has not been through rigorous human trials. The biological rationale is strong; the clinical evidence for this product and protocol is weak.